AR032073A1 - Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas - Google Patents

Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas

Info

Publication number
AR032073A1
AR032073A1 ARP010106066A ARP010106066A AR032073A1 AR 032073 A1 AR032073 A1 AR 032073A1 AR P010106066 A ARP010106066 A AR P010106066A AR P010106066 A ARP010106066 A AR P010106066A AR 032073 A1 AR032073 A1 AR 032073A1
Authority
AR
Argentina
Prior art keywords
peptides
proteins
anphifilic
incorporation
lipid nanoparticles
Prior art date
Application number
ARP010106066A
Other languages
English (en)
Spanish (es)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of AR032073A1 publication Critical patent/AR032073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP010106066A 2000-12-27 2001-12-27 Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas AR032073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128555 2000-12-27
EP01125742 2001-10-26

Publications (1)

Publication Number Publication Date
AR032073A1 true AR032073A1 (es) 2003-10-22

Family

ID=26071689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106066A AR032073A1 (es) 2000-12-27 2001-12-27 Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas

Country Status (15)

Country Link
US (1) US20040081688A1 (el)
EP (1) EP1345597B1 (el)
JP (1) JP4072057B2 (el)
AR (1) AR032073A1 (el)
AT (1) ATE374603T1 (el)
AU (1) AU2002226374B2 (el)
CA (1) CA2431888C (el)
CY (1) CY1106995T1 (el)
DE (1) DE60130791T2 (el)
DK (1) DK1345597T3 (el)
ES (1) ES2291379T3 (el)
IL (2) IL156531A0 (el)
PT (1) PT1345597E (el)
SI (1) SI1345597T1 (el)
WO (1) WO2002051390A2 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CA2528095C (en) * 2003-06-04 2014-10-14 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
CA2549966A1 (en) * 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
EP1924248B1 (en) * 2005-09-15 2014-10-22 Council of Scientific and Industrial Research Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
TR201901443T4 (tr) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
US8361494B2 (en) * 2006-03-10 2013-01-29 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
BRPI0719732A2 (pt) * 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
EP2494958A1 (en) * 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
KR100834687B1 (ko) * 2007-02-21 2008-06-02 주식회사 엘지생활건강 히노키티올 함유 지질 나노 입자 및 그의 제조방법
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
CN101322719B (zh) * 2007-06-15 2012-03-07 杭州民生药业有限公司 一种三氧化二砷固体脂质纳米粒及其制剂
WO2010005721A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
JP2012501966A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2590674B1 (en) 2010-07-06 2017-02-22 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
AU2012205315B2 (en) * 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
DE102011116069A1 (de) 2011-10-18 2013-04-18 Dr. Rimpler Gmbh Lipidnanopartikeldispersion, Verfahren zu deren Herstellung sowie ihre Verwendung
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
JP6356678B2 (ja) 2012-09-17 2018-07-11 ファイザー・インク 治療用ナノ粒子を製造する方法
WO2014092596A1 (ru) * 2012-12-12 2014-06-19 Vitkalova Tamara Aleksandrovna Субстанции и фармацевтические композиции на их основе для лечения заболеваний человека, в том числе, для лечения хронических вирусных гепатитов "в" и "с"
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
WO2015148483A1 (en) * 2014-03-24 2015-10-01 University Of Mississippi Systems and methods for preparing solid lipid nanoparticles
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
IL267923B2 (en) * 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
JP2020152673A (ja) 2019-03-20 2020-09-24 株式会社リコー ナノ粒子及びナノ粒子の製造方法、並びに医薬
CN111388451B (zh) * 2020-04-29 2023-05-23 南京工业大学 蛋白自组装铁基纳米粒及其制备方法与抗肿瘤药物递送系统中的应用
EP4221685A1 (en) 2020-09-29 2023-08-09 Oxford University Innovation Limited Stroke treatment
CN113952301A (zh) * 2021-11-17 2022-01-21 胡振华 中链脂肪酸作为促吸收剂制备药物组合物乳剂的应用
DE202023100649U1 (de) 2023-02-10 2023-03-22 Cineolux Gmbh Dispersion und Zubereitung zur topischen Anwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
IT1296914B1 (it) * 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration

Also Published As

Publication number Publication date
IL156531A (en) 2008-11-03
US20040081688A1 (en) 2004-04-29
EP1345597A2 (en) 2003-09-24
PT1345597E (pt) 2007-10-29
IL156531A0 (en) 2004-01-04
JP4072057B2 (ja) 2008-04-02
ES2291379T3 (es) 2008-03-01
WO2002051390A2 (en) 2002-07-04
DE60130791T2 (de) 2008-07-17
SI1345597T1 (sl) 2007-12-31
CY1106995T1 (el) 2012-09-26
ATE374603T1 (de) 2007-10-15
CA2431888C (en) 2010-06-01
AU2002226374B2 (en) 2006-06-08
EP1345597B1 (en) 2007-10-03
DK1345597T3 (da) 2007-12-10
CA2431888A1 (en) 2002-07-04
JP2004519447A (ja) 2004-07-02
DE60130791D1 (de) 2007-11-15
WO2002051390A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AR032073A1 (es) Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
AR036852A1 (es) Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
HUP0204137A2 (hu) Fulvesztrantot tartalmazó gyógyászati készítmény
ATE226815T1 (de) Herstellung von arzneimitteln
HK1062264A1 (en) Rapidly disintegrating tablet comprising an acid-labile active ingredient
HUP0201637A2 (hu) Savval szemben labilis vegyületet tartalmazó új készítmény és adagolási forma
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
DE60036199D1 (de) Proteaseresistente flint-analoge
AR034853A1 (es) Secuencia de acido nucleico sintetico que codifica una alfa-galactosidasa, vector y celula que la comprenden, metodo para producir alfa-galactosidasa, metodo para prepararla, composicion farmaceutica que comprende dicha secuencia y su uso para preparar esta ultima
AR011707A1 (es) Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento.
AR004354A1 (es) Nuevos antagonistas de lh-rh con efecto mejorado, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y susaplicaciones para la preparacion de medicamentos.
DE69803772T2 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
ES2062254T3 (es) Nuevos preparados medicinales que contienen una sal metalica de ibuprofeno y procedimiento para la preparacion de los mismos.
ECSP024336A (es) Una forma de unidad de dosis farmaceutica del tipo de capsulas rigidas que contiene clonixinato de lisina, un procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y/o inflamatorio
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure